A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma  by Chen, Lu et al.
ORIGINAL ARTICLEA Sensitive NanoString-Based Assay to Score STK11
(LKB1) Pathway Disruption in Lung AdenocarcinomaLu Chen, PhD,a,b Brienne E. Engel, PhD,a Eric A. Welsh, PhD,b Sean J. Yoder,c
Stephen G. Brantley, MD,d Dung-Tsa Chen, PhD,b Amer A. Beg, PhD,e
Chunxia Cao, PhD,f Frederic J. Kaye, MD,f Eric B. Haura, MD,g
Matthew B. Schabath, PhD,h W. Douglas Cress, PhDa,*
aDepartment of Molecular Oncology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
bDepartment of Biostatistics and Bioinformatics, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
cMolecular Genomics Core, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
dPathology Services M2Gen, Tampa, Florida
eDepartment of Immunology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
fDepartment of Medicine, University of Florida, Gainesville, Florida
gDepartment of Thoracic Oncology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
hDepartment of Cancer Epidemiology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, Florida
Received 5 October 2015; revised 22 January 2016; accepted 6 February 2016
Available online - 22 February 2016*Corresponding author.
Drs. Chen and Engel contributed equally to this work.
Disclosure: The authors declare no conﬂict of interest.
Address for correspondence: W. Douglas Cress, PhD, H. Lee Mofﬁtt
Cancer and Research Institute, 12902 Magnolia Drive, Tampa,
FL 33612. E-mail: Douglas.Cress@mofﬁtt.org
ª 2016 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
ISSN: 1556-0864
http://dx.doi.org/10.1016/j.jtho.2016.02.009ABSTRACT
Introduction: Serine/threonine kinase 11 gene (STK11), bet-
ter known as liver kinase b1, is a tumor suppressor that is
commonly mutated in lung adenocarcinoma (LUAD). Previous
work has shown that mutational inactivation of the STK11
pathway may serve as a predictive biomarker for cancer treat-
ments, including phenformin and cyclooxygenase-2 inhibition.
Although immunohistochemical (IHC) staining and diagnostic
sequencing are used to measure STK11 pathway disruption,
there are serious limitations to these methods, thus empha-
sizing the importance of validating a clinically useful assay.
Methods: An initial STK11 mutation mRNA signature was
generated using cell line data and reﬁned using three large,
independent patient databases. The signature was validated
as a classiﬁer using The Cancer Genome Atlas (TCGA) LUAD
cohort as well as a 442-patient LUAD cohort developed at
Mofﬁtt. Finally, the signature was adapted to a NanoString-
based format and validated using RNA samples isolated
from formalin-ﬁxed, parafﬁn-embedded tissue blocks cor-
responding to a cohort of 150 patients with LUAD. For
comparison, STK11 IHC staining was also performed.
Results: The STK11 signature was found to correlate with
null mutations identiﬁed by exon sequencing in multiple
cohorts using both microarray and NanoString formats.
Although there was a statistically signiﬁcant correlation
between reduced STK11 protein expression by IHC staining
and mutation status, the NanoString-based assay showed
superior overall performance, with a –0.1588 improvement
in area under the curve in receiver-operator characteristic
curve analysis (p < 0.012).Journal of Thoracic Oncology Vol. 11 No. 6: 838-849Conclusion: The described NanoString-based STK11 assay
is a sensitive biomarker to study emerging therapeutic
modalities in clinical trials.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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inhibitionIntroduction
Serine/threonine kinase 11 gene (STK11) is a serine/
threonine kinase, also known as liver kinase b1 (LKB1),
that was discovered to be the gene responsible for fa-
milial Peutz-Jeghers syndrome.1 Although somatic STK11
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lung squamous cell carcinoma,2 the incidence of STK11
mutations in lung adenocarcinoma (LUAD) is exceeded
only by that of Kirsten rat sarcoma viral oncogene ho-
molog gene (KRAS) and tumor protein p53 gene (TP53)
mutations.3–10 The STK11 protein is catalytically active
as a heterotrimeric complex with the STE20-related
adaptor protein a and mouse protein 25 (MO25). Many
mutations in STK11 have been found to interfere with its
ability to bind these partners,11 rendering the expressed
protein inactive. STK11 has multiple targets that likely
mediate its tumor suppressor activity. Foremost, STK11
is responsible for phosphorylating the adenosine
monophosphate (AMP)-activated kinase (AMPK) at
amino acid residue T172 under conditions of energy
stress.12 Our published work links STK11 to the regula-
tion of cyclooxygenase 2 (COX-2) and many other genes
through indirect regulation of the CREB-regulated tran-
scription coactivator 1 transcription factor.13–15 Addi-
tionally, we ﬁnd that STK11 mutations can be linked to
immunosuppression through potential inﬂuence on the
nuclear factor k light-chain enhancer of activated B cells
signaling pathway.16
Although there are currently no drugs in routine
clinical use that speciﬁcally target STK11 there is a
growing number of approaches that may differentially
beneﬁt patients with disrupted STK11.17–25 Therapies
that reactivate AMPK, such as metformin, phenformin,20
and 5-aminoimidazole-4-carboxamide ribonucleotide,22
and an AMP mimetic (2-deoxyglucose)21 have been
shown to render STK11-mutant tumors more susceptible
to chemotherapies, possibly by promoting a transition
from adenocarcinoma to squamous cell carcinoma.17
Recent work suggests that STK11 mutation enhances
the sensitivity to energetic stress that is induced by
erlotinib treatment.25 Additionally, drugs that target the
downstream proteins that are up-regulated by loss of
STK11, such as mammalian target of rapamycin (mTOR)
inhibitors (e.g., rapamycin24 and everolimus23), cyclo-
oxygenase 2 (COX-2) inhibitors (e.g., NS-398 and niﬂu-
mic acid13), reactive oxygen species–inducing agents,17
and lysyl oxidase inhibitors (e.g., BAPN b-amino-
propionitrile26), have shown efﬁcacy in STK11-mutant
cells as compared with their wild-type (WT) counter-
parts. In summary, despite extensive preclinical data, the
lack of progress in developing clinical treatments for
patients with STK11-null cancers is partly due to the lack
of a validated method to reliably score STK11 status
using available formalin-ﬁxed, parafﬁn-embedded
(FFPE) archival samples.
Immunohistochemical (IHC) staining27 and diagnostic
sequencing are both potential means to measure STK11
pathway disruption. However, many of the variants
identiﬁed in STK11 lead to single amino acid changes thatmay not alter STK11 function.16,28 Furthermore, STK11
function can be lost by epigenetic inactivation29 or by
homozygous and intragenic deletions,7,30 which are
difﬁcult to detect by genomic sequencing. In fact, recent
work suggests that as many as one-half of instances of
STK11 functional loss are undetected by sequencing.31
Given the potential of assessing STK11 status as a
biomarker in LUAD, a robust STK11 mutation signature
was adapted into a format based on NanoString Elements
(NanoString Technologies Inc., Seattle, WA) that is
amenable to use with FFPE samples. This assay was then
validated using RNA isolated from tissue blocks from a
cohort 150 LUAD surgical specimens. For comparison,
STK11 IHC staining was performed. The results demon-
strate that the NanoString-based assay yields overall
performance superior to that of STK11 IHC staining,
suggesting that NanoString may be a useful tool in a
multianalyte approach to identify patients with LUAD
with disruption of the STK11 pathway.
Materials and Methods
Expression Vectors, Cell Culture, and Molecular
Assays
Detailed methods are provided in the Supplementary
Materials. Brieﬂy, the pcDNA3-FLAG-STK11 vector
(plasmid 8590) was purchased from Addgene (Cam-
bridge, MA). pNTAPb and the pNTAPb-Mef2a afﬁnity-
tagged negative control (kit 240103) were purchased
from Agilent Technologies (Santa Clara, CA) as a
component of the InterPlay N-terminal Mammalian TAP
System. Cells were cultured in Roswell Park Memorial
Institute medium supplemented with 10% fetal bovine
serum and transfected with a vector (pNTAPb), Mef2a
control, or one of three STK11 variants (D194Y,
P281fs*6, or F354L) with Lipofectamine-2000 (Thermo
Fisher Scientiﬁc, Waltham, MA) in serum-free media.
Proteins were visualized using horseradish peroxidase–
conjugated secondary antibodies and enhanced chem-
iluminescence (GE Healthcare Life Sciences, Pittsburgh,
PA). NanoString assays were performed with 150-ng
aliquots of RNA using the NanoString nCounter Anal-
ysis system (NanoString Technologies). Tissue micro-
array (TMA) slides were cut into 4-mM sections and
stained with anti-STK11 (Santa Cruz Biotechnology,
Santa Cruz, CA) at a 1:100 dilution.
Clinical and Molecular Data Sets
Five public data sets were used: (1) the Molecular
Classiﬁcation of Lung Adenocarcinoma (MCLA) micro-
array study32, (2) the Cancer Genome Atlas (TCGA)
LUAD RNAseq study,28 and (3 through 5) three micro-
array studies from the Gene Expression Omnibus33
(GSE30219,34 GSE37745,35 and GSE1481436). The
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the MCLAþ cohort. Data from a cohort of 442 patients
with LUAD (herein referred to as the Mofﬁtt LUAD
overall survival [MLOS] cohort) who consented to the
Mofﬁtt Cancer Center’s Total Cancer Care Protocol (see
Supplementary Table 1) was also used. Surgical tissue
blocks from 150 patients (see Supplementary Table 2)
who were treated at Mofﬁtt were used to construct a
TMA as described in the Supplementary Methods and as
the source for RNA for NanoString analysis. Herein,
these 150 patients are referred to as the Mofﬁtt LUAD,
Complete cohort because it was possible to acquire
medical charts and tissue blocks for these patients. Most
members of the Mofﬁtt LUAD, Complete are also in the
MLOS cohort. All patient-related work was approved by
the University of South Florida Institutional Review
Board.
Statistical Analysis
Statistical analyses were performed using R Project
for Statistical Computing, version 3.2.2,37 and SAS 9.4
software (SAS Institute, Cary, NC). The chi-square test
exact method with Monte Carlo estimation was used
to test for differences in the distributions of muta-
tional status by study population characteristics.
Principal component analysis (PCA) was used to
summarize STK11 signature scores in a single number.
Brieﬂy, PCA is used to ﬁnd orthogonal vectors that
capture the largest sources of variance within a data
set.38,39 The scores from the ﬁrst principal component
of a gene signature are commonly used to score
samples within a data set. The gene loadings, p[1],
corresponding to the ﬁrst principal component, reﬂect
the relative weights of each gene with respect to their
contribution to the sample scores. The second prin-
cipal component in our analyses did not correlate with
STK11 mutation status; however, it was used as a
means to plot the ﬁrst principal component in two
dimensions.
Measures of test performance and agreement of the
STK11 gene signature to predict STK11 mutation status,
including true positives, true negatives, false positives,
false negatives, sensitivity, speciﬁcity, negative predic-
tive value, false-positive rate, and false discovery rate,
were calculated. For the TCGA samples, the ﬁrst prin-
cipal component of the STK11 signature (t[1]) was used
to assign WT and STK11 phenotypes (WT: t[1]  0;
STK11: t[1] > 0) to the samples. The MLOS cohort
sample phenotypes were assigned in a similar fashion
(WT: t[1]  2.1; STK11: t[1] > 2.1). Splice site muta-
tions were treated as mutant for two-state analysis
purposes. Receiver operating characteristic curves
were used to compare overall assay sensitivity andspeciﬁcity on the basis of area under the curve (AUC)
calculations.Results
Expression of Stable, but Catalytically Inactive
STK11 Variants May Obscure STK11 Pathway
Mutations
Previous work has identiﬁed three alternatively
spliced isoforms of STK11: (1) the full-length 50-kDa
isoform; (2) a 48-kDa isoform with an alternative C-
terminus that is expressed in the testis40; and (3) an
oncogenic, but kinase-inactive 42-kDa isoform that is
mainly expressed in normal heart and skeletal muscle41
and is reported to be expressed (along with other
shortened STK11 isoforms) at high levels in tumors with
mutations in STK11 codons 1 and 2.42 Such isoforms
could potentially obscure standard assessment of STK11
pathway status by IHC staining. Thus, we sought to
examine the expression of STK11 isoforms in established
cells lines and tumors. Forty-two cell lines and 56 tumor
samples with known STK11 status were examined by
STK11 Western blotting (Fig. 1). Figure 1A reveals that
as expected, the full-length 50-kDa STK11 band was
present in STK11 WT cell lines, with H2170 cells being
the exception. The 48-kDa isoform was observed in only
two cell lines (H292 and HCC4006, both STK11 WT) and
was coexpressed with the 50-kDa band. In H2170, H520,
H1395, Calu-6, and H1581 cells intense faster migrating
bands were observed in the 42-kDa range and were
generally coexpressed with the 50-kDa isoform. Full-
length STK11 protein expression was absent in all
STK11 mutant cell lines, as expected.
In patient tumor samples, STK11 Western blotting
revealed a wide range of protein isoform expression for
both STK11 WT and variant tumors (Fig. 1B). Expression
of both the 42- and 48-kDa isoforms was much more
common in tumors than in cell lines, and in many tumors
the shorter isoforms were expressed at higher levels
than the full-length protein was. We did not observe
expression of the 42-kDa isoform to be correlated with
STK11 mutations as previously reported.42 Considering
only the 50-kDa full-length protein, many STK11 WT
tumors expressed less STK11 protein than did STK11
variant tumors. Figure 1B highlights three examples of
common or recurring STK11 variants (D194Y, F354L
and P281fs*6), which were further explored. The STK11
variants D194Y and F354L expressed high protein
levels in four patients, whereas a patient with the
P281fs*6 variant (and other similar frameshift variants)
expressed very little STK11 protein. The F354L variant,
which has previously been found in Asian populations
with a frequency of approximately 10%,43 is likely a
Figure 1. Serine/threonine kinase 11 (STK11) protein expression in cell lines and tumor samples. (A) Cell lines and (B) patient
tumors with previously determined serine/threonine kinase 11 gene (STK11) mutational status16 were subjected to Western
blotting for STK11. Samples speciﬁcally highlighted in the text are boxed. Repeated cell lines were obtained from different
laboratory sources. The three STK11 isoforms are indicated. (C) Empty pNTAPb vector (Vector), a vector expressing a
negative control afﬁnity-tagged Mef2a protein (Mef2a control), wild-type (WT) STK11, and each of the three indicated STK11
variants were transfected into H1299 cells, immunoprecipitated using streptavidin beads, and blotted for binding to mouse
protein 25 (MO25) and STE20-related adaptor protein a (STRAD). (D) A549 cells were transfected with the indicated com-
bination of plasmids, extracted and blotted for adenosine monophosphate–activated kinase (AMPK) phosphorylated at T172,
total AMPK, and b-actin. The ﬁrst lane (–) represents empty vectors (pcDNA3 and pNTAPb), the second lane (þ) represents
cells transfected with pcDNA3 WT STK11 and empty pNTAPb, and the lanes labeled D194Y received pNTAPb-D194Y alone (–) or
pNTAPb-D194Yplus WT in 1:1 (þ), 1:5 (þþ), and 1:10 (þþþ) ratios. Lanes labeled F354L received pNTAPb-F354L alone (–) or
pNTAPb-F354L plus WT in 1:1 (þ), 1:5 (þþ), and 1:10 (þþþ) ratios.
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Figure 2. Validation of the serine/threonine kinase 11 (STK11) mutation signature in two large patient-derived data sets.
(A, B) PCA was performed on the indicated patient-derived data sets using the reﬁned STK11 signature. Summary signature
scores for ﬁrst the ﬁrst and second principal components for each individual patient are plotted. Patients with wild type (WT)
STK11 are plotted with green symbols, splice-site variants are plotted in blue, exon mutations are plotted with yellow
symbols and The Cancer Genome Atlas (TCGA) samples of unknown mutation status are plotted in red. (C, D) ROC curves for
the TCGA and Mofﬁtt lung adenocarcinoma overall survival (MLOS) cohorts.
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Table 1. Measures of Test Performance between the STK11 Signature and Detected DNA Variation in TCGA and the MLOS
Cohorts
Detected DNA Variation Signature Prediction c Class Metric p Value 95% CI
TCGA
Mutant STK11þ 71 TPs Sensitivity 0.947 (0.869–0.985)
Mutant WT 4 FNs Speciﬁcity 0.732 (0.686–0.77)
WT STK11þ 109 FPs Precision 0.394 (0.322–0.469)
WT WT 298 TNs NPV 0.987 (0.966–0.996)
False-positive rate 0.268 (0.22–0.313)
False discovery rate 0.606 (0.53–0.677)
MLOS
Mutant STK11þ 66 TPs Sensitivity 0.971 (0.897–0.996)
Mutant WT 2 FNs Speciﬁcity 0.741 (0.693–0.784)
WT STK11þ 97 FPs Precision 0.405 (0.328–0.484)
WT WT 277 TNs NPV 0.993 (0.974–0.999)
False-positive rate 0.259 (0.215–0.306)
False discovery rate 0.595 (0.515–0.671)
STK11, serine threonine kinase 11 gene; TCGA, The Cancer Genome Atlas; MLOS, Mofﬁtt lung adenocarcinoma overall survival cohort; TPs, true positives; FNs,
false negatives; WT, wild type, FPs, false positives; NPV, negative predictive value; TNs, true negatives.
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because it has also been reported to affect cell polarity
through an AMPK-dependent mechanism.44 First,
whether these three variants could bind the other
members of the catalytically active STK11 trimeric
complex, MO25 and STE20-related adaptor protein a
(STRAD), was determined. A negative control vector, WT
STK11, or each of the three variants was then transfected
into H1299 cells and the extracts were subjected to
coimmunoprecipation with STK11 antibody/streptavidin
beads. The exogenous WT STK11, as well as the D194Y
and F354L variants, were stably expressed and efﬁ-
ciently coimmunoprecipitated MO25 and STRAD
(Fig. 1C) relative to the control vector. However, the
P281fs*6 mutant was unstable (as expected) and did not
coimmunoprecipate either MO25 or STRAD. Next, the
two stable variants were tested for dominant negative
activity by transfecting the variant alone and the variant
plus WT STK11 (in 1:1, 1:5, and 1:10 ratios) into A549
cells lacking endogenous STK11. Catalytic activity was
measured by examining downstream phosphorylation of
AMPK by using a phospho-speciﬁc antibody. The D194Y
mutant was able to suppress activation of AMPK by the
WT STK11 at all ratios examined (Fig. 1D). Conversely,
the F354L variant phosphorylated AMPK in the presence
or absence of WT protein and is therefore likely a
common polymorphism.Development and Validation of a 122-Gene
STK11 Mutation Signature
Cell line data and three published Affymetrix-based
gene expression databases32,34,35 representing nearly
1000 patients with non–small cell lung cancer were used
to develop and reﬁne a 122-gene STK11 mutation
signature. Development of this signature is described inthe Supplementary Materials and the included genes
along with their relative contributions (loading co-
efﬁcients) to the PCA-based signature are listed in
Supplementary Table 7. The ability of this STK11 signa-
ture to classify LUAD tumors from two large data sets
with available expression and mutation and copy number
data was tested using the TCGA LUAD RNAseq data set,28
including 488 patient samples and a second recently
described16 microarray-based expression data set from
442 patients with LUAD (herein referred to as the MLOS
cohort, described in Supplementary Table 1). Figures 2A
and 2B show the results of PCA analysis of the two large
patient data sets, in which the ﬁrst principal component
(the STK11 score, x axis) and the second principal
component (unrelated to STK11mutation, y axis) for each
patient (color coded as either STK11 WT or one of three
types of mutations) are plotted. Various measures of
agreement with sequenced STK11 mutation status were
then calculated (Table 1) and demonstrated that the
sensitivity of the signature relative to determined muta-
tions is good (0.95–0.97) but speciﬁcity (0.73–0.74) is
poor when sequencing is used as the standard. These are
the expected results because there may be many tumors
with WT STK11 DNA that down-regulate the STK11
protein or pathway by other mechanisms.27,31Adaptation of the STK11 Signature to Clinical
Specimens Using NanoString
Given the potential of assessing STK11 status as a
clinical biomarker, the STK11 mutation signature was
adapted into a NanoString Elements–based format (see
Supplementary Tables 3–5) that is amenable to use with
FFPE samples. NanoString assays utilize ﬂuorescently
barcoded probes that hybridize to targeted RNA mole-
cules ﬁxed to a slide. Advantages of the technology
Figure 3. A NanoString-based serine/threonine kinase 11 gene (STK11) assay applied to clinical samples. (A) Principal
component analysis using 122 NanoString codesets was performed on 140 RNA samples isolated from formalin-ﬁxed, plasma-
embedded (FFPE) blocks, and the loading coefﬁcients from the ﬁrst (p[1]) and second (p[2]) principal components from
human tumors were plotted. The signal variation covered by each principal component is indicated as a percentage of total
variation. Blue symbols represent probesets with a negative loading coefﬁcient in cell lines and red symbols represent those
with positive values in cell lines. (B) Summary signature scores for ﬁrst (PC 1) and second (PC 2) principal components for
each individual patient are plotted. See Materials and Methods for details of the analysis. Patients with wild-type (WT)
mutations are plotted with green symbols, splice site variants are plotted in blue, and exon mutations are plotted with yellow
symbols. (C–F) Waterfall plots of the NanoString-based STK11 signature score. The number of WT and mutant (MUT) samples
are indicated for each gene. p Values indicating correlation by the Wilcoxon rank sum test demonstrated signiﬁcant corre-
lation with STK11 and epidermal growth factor receptor gene (EGFR) (mutually exclusive) mutation status. (C) STK11, (D)
Kirsten rat sarcoma viral oncogene homolog gene (KRAS), (E) tumor protein p53 gene (TP53), and (F) EGFR.
844 Chen et al Journal of Thoracic Oncology Vol. 11 No. 6include the following: (1) it does not contain any enzy-
matic steps that can be inhibited by contaminants; (2)
the assay works well on the partially degraded RNA that
is generally retrieved from ﬁxed tissues; and (3) because
RNA molecules are detected and counted individually,
the data analysis is simple. This NanoString panel was
used to examine RNA samples isolated from parafﬁn
blocks from a cohort of 150 patients with LUAD
(Supplementary Table 2). Of the 150 blocks, 10 did not
yield adequate NanoString counts when 150 ng of RNA
was used. Figure 3 highlights the results of PCA.
Figure 3A demonstrates that the loading coefﬁcients of
most genes in the signature have the same sign as in cell
lines despite the great difference in source material
(fresh frozen tissue versus ﬁxed tissue) and in spite of
the difference in methodology (microarray versus
NanoString). Figure 3B demonstrates that the ﬁrst
principal component signiﬁcantly segregates STK11 WT
and mutant tumors. Figures 3C through 3F show
waterfall plots of the ﬁrst principal component score of
each patient, highlighting patients with mutations in
STK11, KRAS, TP53, or epidermal growth factor receptor
gene (EGFR) in red. Clearly, the signature correlates withSTK11 mutations (Wilcoxon rank sum test, p < 0.0001),
whereas mutations in KRAS and TP53 do not show a
statistically signiﬁcant tendency (p ¼ 0.9965 and p ¼
0.2548, respectively) in spite of the fact that STK11 and
KRAS mutations are known to favor co-occurrence (p ¼
0.003).45 In contrast, EGFR mutants have a signiﬁcantly
lower STK11 score (Wilcoxon rank sum test, p <
0.0132), which would be expected because STK11 and
EGFR mutations are mutually exclusive in LUADs.45
Direct Comparison between STK11 IHC Staining
and NanoString
Previous work has demonstrated STK11 IHC staining
as a means to assess STK11 mutation status.27 Having
established in Figure 1B that direct measurement of
STK11 protein in patient tumors might have complica-
tions, STK11 IHC staining and the STK11 NanoString
assay were directly compared. To do this, a tissue
microarray representing cell lines of known STK11 sta-
tus (Fig. 1A), 54 normal lung tissue cores, and 140 LUAD
tumors (135 of which were also assayed by STK11
NanoString) was stained with STK11 antibody, as pre-
viously described.27 Comparison of the IHC staining of
Figure 3. (continued).
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STK11 protein (Fig. 1A), and A549 cells (Fig. 4Aii),
which express no STK11 (Fig. 1A), demonstrates the
speciﬁcity of the STK11 IHC staining. Figures 4Aiii and
4Aiv demonstrate that STK11 staining in normal lung
epithelial tissue (alveolar or bronchial) was generally
light, cytoplasmic, and diffuse and was set to a maximum
value of þ4. IHC staining scores of tumor tissue ranged
from þ4 to 0 (see Supplementary Fig. 2 for examples of
each) and the IHC staining scores for the various cores
are listed in Table 2. Figures 4Av and Avi highlight two
carcinomas with an IHC staining score of þ4 that are
STK11 WT and mutant, respectively. Figures 4Avii and
Aviii highlight two STK11 IHC staining–negative carci-
nomas that are STK11 WT and mutant, respectively.
These examples demonstrate the potential limitations of
STK11 IHC staining. Figure 4B compares STK11 IHC
staining with STK11 NanoString assay using receiver
operator characteristics modeling. For the NanoString
assay, the AUC (or C-statistic) was 0.8377, whereas IHC
staining achieved an AUC of only 0.6789. Thus, the
NanoString-based assay shows superior overall perfor-
mance, with a 0.1588 improvement in AUC relative to
IHC staining (p < 0.0119, see Table 2).Discussion
This work describes a NanoString-based assay that
can assess deregulation of the STK11 pathway in patient
samples derived from FFPE tissues. The genes
comprising the assay were validated in multiple data
sets representing six different studies examining a total
of 1894 patient samples, and the assay itself was further
validated using RNA isolated from FFPE tissues. Because
anti-STK11 antibodies can cross-react with nonspeciﬁc
species and occasional null mutations do not affect
STK11 steady-state protein levels, this assay showed a
higher sensitivity and speciﬁcity than did STK11 IHC
staining using exome sequencing as the standard.16 In
data not shown, no correlation between STK11 mutation
status and cell cycle progression, whether measured by
Ki-67 staining or by assessment of a previously deﬁned
proliferative signature, was observed.46 Nor was any
statistically signiﬁcant prognostic value associated with
STK11 mutations or the STK11 signature whether
considered alone or in the context of concurrent KRAS or
TP53 mutations. Finally, analysis did not reveal any as-
sociation between STK11 disruption and metastasis
among patients with KRAS mutations, as has been pre-
viously shown.27
Figure 4. Direct comparison between serine/threonine kinase 11 (STK11) immunohistochemical (IHC) staining and Nano-
String. STK11 IHC staining was performed on a tissue microarray representing cell lines, normal tissues, and lung adeno-
carcinoma tumors (Mofﬁtt LUAD, Complete cohort). Scale bar represents 200 mM. (A) STK11 IHC staining in representative
cores: (i) core 231, H1299 cells with WT STK11 and expression of the 52-kDa isoform (see Fig. 1A); (ii) core 207, A549 cells
with mutant STK11 and lacking expression of any STK11 isoform (see Fig. 1A); (iii) core 141, normal alveolar tissue, þ4
staining; (iv) core 78, normal bronchial tissue, þ4 staining; (v) core 1, carcinoma with WT STK11, þ4 staining; (vi) core 139,
carcinoma with mutant STK11, þ4 staining; (vii) core 29, carcinoma with WT STK11, 0 staining, negative; and (viii) core 66,
carcinoma with mutant STK11, 0 staining, negative. (B) Receiver operating characteristic (ROC) curves comparing STK11
NanoString with IHC staining (area under the curve [AUC] was 0.8377 for NanoString versus 0.6789 for IHC staining).
Supplementary Table 6 identiﬁes cores by STK11 mutation status.
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Table 2. STK11 IHC Staining Results and Test Performance
Comparison with the STK11 NanoString Assay
IHC Pathology Score
No. Patients with Indicated IHC
Staining Scores
0 þ1 þ2 þ3 þ4
Normal cores 0 0 0 3 51
Carcinomas
STK11 mutant 7 6 2 5 7
STK11 WT 15 6 6 18 68
Receiver Operator Characteristics Modeling
Model AUC 95% CI
Difference in AUC
and 95% CI
p
Value
NanoString 0.8377 (0.76–0.9154) 0.1588 (0.035–0.2825) 0.0119
IHC
pathology
score
0.6789 (0.566–0.7918)
STK11, serine threonine kinase 11; IHC, immunohistochemical; STK11, serine
threonine kinase 11 gene; WT, wild type; AUC, area under the curve, CI,
conﬁdence interval.
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as the standard procedure to be subsequently tested
along with a combination of exon sequencing and IHC
staining as predictive biomarkers for newly emerging
immunotherapies16 or other anticancer treatments
exploiting AMPK activation, such as metformin/phen-
formin or COX-2 inhibition studies.13 This NanoString-
based STK11 assay will likely emerge as the best of the
three methods for several reasons. First, the assay is
based on a very comprehensive examination of existing
data on STK11 incorporating both extensive cell line data
as well as thousands of patient samples. The strong
recapitulation of the cell line data into patient samples
supports the robust nature of the assay and preservation
of at least a subset of the critical biological pathways
disrupted downstream of STK11 mutations. The fact that
the signature has been validated in multiple human tis-
sue data sets with multiple technical methodologies
(including microarray, RNA Seq and NanoString) ensures
that the signature it is likely to be broadly applicable
going forward. In fact, during the development of this
STK11 signature, a 16-gene STK11 signature (classiﬁer)
was published.31 Ten of the 16 genes in the published
signature are also in our signature, suggesting signi-
ﬁcant convergence of the best classiﬁers using different
approaches. In our analysis, nine of these 10 genes had
individual p values less than 0.05, suggesting that they
will translate very well. We also note that the
NanoString-based assays are emerging as a reliable and
highly general and ﬂexible method to assess gene
expression in very limited ﬁxed tissues.47 A NanoString-
based version of the prediction analysis of microarray50 panel was recently U.S. Food and Drug Administra-
tion approved for prognosis in breast cancer.48 We ﬁnd
the NanoString methodology to be highly reproducible,
and given its general simplicity, we anticipate that it
will be readily adapted clinically as an alternative to
quantitative polymerase chain reaction and sequencing
methods. The straightforward multiplex nature of the
NanoString assay will allow us to further optimize the
codesets included in the assay as additional data are
acquired.
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